Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia

American Journal of Epidemiology

Volumn 164, Issue 8, 2006, Pages 760-768

  St Sauver, Jennifer L ^a,c   Jacobson, Debra J ^a   Mcgree, Michaela E ^a   Lieber, Michael M ^a   Jacobsen, Steven J ^b  

^a Mayo Clinic   (United States)

^b KAISER PERMANENTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Anti inflammatory agents; Cohort studies; Data collection; Men; Non steroidal; Prostate specific antigen; Prostatic hyperplasia; Questionnaires

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTATE SPECIFIC ANTIGEN;

COHORT ANALYSIS; DRUG; MALE; RISK FACTOR;

ADULT; AGE; AGED; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX SCORE; ARTICLE; BLOOD LEVEL; CAUCASIAN; COHORT ANALYSIS; DISEASE SEVERITY; DRUG UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RISK ASSESSMENT; SCORING SYSTEM; SYMPTOMATOLOGY; TRANSRECTAL ULTRASONOGRAPHY; UNITED STATES; URINARY TRACT OBSTRUCTION; URINE FLOW RATE; VALIDATION PROCESS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; LEAST-SQUARES ANALYSIS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MINNESOTA; PROPORTIONAL HAZARDS MODELS; PROSTATIC HYPERPLASIA; QUESTIONNAIRES;

MINNESOTA; NORTH AMERICA; OLMSTED COUNTY; UNITED STATES;

EID: 33749460341     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwj258     Document Type: Article

References (31)

1. Sarma AV, Wei JT, Jacobson DJ, et al. Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. Urology 2003;61:1086-91.
2. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med 1995;155:477-81.
3. Wei JT, Calhoun EA, Jacobsen SJ. Benign prostatic hyperplasia. In: Litwin MS, Saigal CS, eds. Urologic diseases in America. Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, US Government Publishing Office, 2004:43-67. (NIH publication no. 04-5512).
4. Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 1992;14:131-53.
5. Emberton M, Andriole GL, de la Rosette J, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003;61:267-73.
6. Oesterling JE, Martin SK, Bergstralh EJ, et al. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993;269:57-60.
7. Lieber MM, Jacobsen SJ, Roberts RO, et al. Prostate volume and prostate-specific antigen in the absence of prostate cancer: a review of the relationship and prediction of long-term outcomes. Prostate 2001;49:208-12.
8. Gerstenbluth RE, Seftel AD, MacLennan GT, et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation. J Urol 2002;167:2267-70.
9. Nickel JC, Downey J, Young I, et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84:976-81.
10. Anim JT, Udo C, John B. Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 1998;100:439-49.
11. Wang W, Bergh A, Damber JE. Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004;61:60-72.
12. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003;43:164-75.
13. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004;90:93-9.
14. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002;77:219-25.
15. Irani J, Ravery V, Pariente JL, et al. Effect of nonsteroidal antiinflammatory agents and finasteride on prostate cancer risk. J Urol 2002;168:1985-8.
16. Perron L, Bairati I, Moore L, et al. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003;106:409-15.
17. Zha S, Yegnasubramanian V, Nelson WG, et al. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 2004;215:1-20.
18. Meigs JB, Mohr B, Barry MJ, et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935-44.
19. Kang D, Andriole GL, Van De Vooren RC, et al. Risk behaviours and benign prostatic hyperplasia. BJU Int 2004;93:1241-5.
20. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: factors associated with discordance between frequency and bother of urinary symptoms. Urology 1993;42:663-71.
21. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85-9.
22. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-74.
23. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-57.
24. Girman CJ, Jacobsen SJ, Guess HA, et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995;153:1510-15.
25. Feldman HA. Families of lines: random effects in linear regression analysis. J Appl Physiol 1988;64:1721-32.
26. Ware JH. Linear models for the analysis of longitudinal studies. Am Stat 1985;39:95-101.
27. Pan Y, Zhang JS, Gazi MH, et al. The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2003;12:769-74.
28. Zhu W, Smith A, Young CY. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology 1999;140:5451-4.
29. Kyprianou N, Tu H, Jacobs SC. Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-75.
30. Di Silverio F, Bosman C, Salvatori M, et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur Urol 2005;47:72-9.
31. Prevalence of aspirin use to prevent heart disease-Wisconsin, 1991, and Michigan, 1994. MMWR Morb Mortal Wkly Rep 1997;46:498-502.